TrialOpen forum infectious diseases2024

Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort Study.

Marta Vasylyev et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.